An approach for the transition from systemic immunosuppressants to dupilumab

TY - JOUR

T1 - An approach for the transition from systemic immunosuppressants to dupilumab

AU - de Wijs, L. E.M.

AU - Thyssen, J. P.

AU - Vestergaard, C.

AU - Thio, H. B.

AU - Kunkeler, A. C.M.

AU - Biedermann, T.

AU - Hijnen, D. J.

N1 - Funding Information: L.E.M. de Wijs, H.B. Thio and A.C.M. Kunkeler have none to declare. J.P. Thyssen attended advisory boards for Eli Lilly, Regeneron, Pfizer, LEO Pharma, AbbVie and Sanofi Genzyme; received speaker honorarium from LEO Pharma, AbbVie, Regeneron and Sanofi Genzyme; and received research grants from Regeneron and Sanofi Genzyme. C. Vestergaard has acted as speaker and/or investigator for Sanofi Genzyme, AbbVie, LEO Pharma, Galapagos, Pierre Fabre Dermo‐Cosmetique and Novartis. D.J. Hijnen has been an investigator for AbbVie, LEO Pharma, Galderma, MedImmune/AstraZeneca, Novartis and Sanofi/Regeneron; and consultant for Regeneron/Sanofi, LEO Pharma, MedImmune/AstraZeneca, Novartis, Incyte, Janssen, Pfizer and Lilly. T. Biedermann has been an institution investigator for AbbVie, LEO Pharma, Novartis, Sanofi/Regeneron, Janssen, Pfizer and Lilly; consultant for Alk‐Abelló, Mylan, Novartis and Sanofi/Regeneron; and received honorarium for talks or research grant from Alk‐Abelló, Celgene, Mylan, Novartis, Phadia/Thermo Fisher and Sanofi/Regeneron.

PY - 2021/3

Y1 - 2021/3

UR - http://www.scopus.com/inward/record.url?scp=85092197865&partnerID=8YFLogxK

U2 - 10.1111/jdv.16941

DO - 10.1111/jdv.16941

M3 - Article

C2 - 32920932

AN - SCOPUS:85092197865

SN - 0926-9959

VL - 35

SP - e221-e223

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 3

ER -